Table 2.
Median adherence rates for study activities across disease groups.
|
|
Long COVID-19 (n=49) | Pancreatitis (n=44) | PCDa (n=51) | Sarcoidosis (n=50) | VCPb disease (n=44) |
| Study weeks, mean (SD) | 14.2 (3.6) | 14.5 (3.2) | 11.9 (3.5) | 18.0 (0.6) | 13.7 (3.1) |
| Retention, n (%) | 49 (100) | 42 (95.5) | 47 (92.2) | 47 (94.0) | 44 (100) |
| Biweekly check-in calls (%), median (IQR) | 100 (100-100) | 85.7 (61.7-100) | 71.4 (46.4-92.9) | 85.7 (71.4-100) | 100 (100-100) |
| Daily quick activities (%), median (IQR) | 36.8 (22.1-60.3) | 39.9 (23.5-68.2) | 39.8 (24.2-55.4) | 51.2 (25.1-67.3) | 43.1 (29.7-64.2) |
| Weekly in-app survey (%), median (IQR) | 90.9c (73.3-100) | 97.2c (89.2-100) | 100c (80.2-100) | —d | 72.4e (54.2-80.0) |
| Biweekly in-app survey (%), median (IQR) | 100f (75-100) | 100f (88.9-100) | 100f (79.2-100) | 100f (89.5-100) | 100f (100-100) |
| Oura ring use (%), median (IQR) | 89.3 (71.4-95.0) | 67.1 (46.2-92.5) | 26.3 (15.5-50.4) | 66.4 (52.6-82.1) | 83.9 (65.1-94.1) |
| Empatica Embrace Plus use (%), median (IQR) | 69.9 (39.4-98.2) | 69.7 (29.9-93.1) | — | — | — |
| MIR Spirometer use (%), median (IQR) | — | — | 50.0 (33.3-62.5) | — | 62.5 (47.2-81.7) |
| Lumia use (%), median (IQR) | 62.5 (33.7-80.0) | — | — | — | — |
aPCD: primary ciliary dyskinesia.
bVCP: valosin-containing protein.
cWeekly Fatigue Assessment Scale.
dNot available.
eWeekly Pain Severity Scale.
f9-item Patient Health Questionnaire.